Adjuvanted Cell-Based Influenza Vaccine Meets Phase 3 Objectives

Evidence Peer-reviewed publication · Discovery September 11, 2026 · Importance 4/5 · Direction Positive Summary A peer-reviewed Phase 3 study of CSL Seqirus’ MF59-adjuvanted, cell-derived, higher-dose quadrivalent influenza vaccine enrolled 7,699 adults aged 50 years or older across eight countries. The investigational vaccine was immunologically…